Bausch Health Companies Inc. (BHC)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 8.10 GTC — a pullback bid to the 8.02–8.14 shelf inside a stacked uptrend (price above SMA20/50/200, ADX 33 rising) — with a protective stop at 7.68 (below the 11-03 swing low 7.87, floored at 1.0×ATR), targets 8.94/9.57 and R/R 2.00; the alternative breakout stop above the settled 8.46 high was rejected at R/R 1.22 running into the 9.04 catalyst-day resistance.
Company overview
Bausch Health Companies Inc. develops, manufactures, and commercializes pharmaceuticals, medical devices, and over-the-counter products, focusing on ophthalmology, digestive health, and dermatology. It operates through divisions like Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products, with a global presence.
Fundamental
fairBausch Health shows strong cash generation but faces leverage constraints and a looming patent cliff.
Mixed, cash-rich, leverage-constrained: Bausch Health generates roughly $1.8 billion of free cash flow a year with 72% gross margins and improving 2026 interim revenue and segment profit, but carries about $18 billion of net debt against negative shareholders' equity, pays deep-junk credit spreads, and faces a 2027-2028 Xifaxan pricing and patent cliff. The weak trailing GAAP loss is a non-cash impairment artifact rather than an operating collapse; the real question is how much of that cash flow survives the cliff.
Sentiment
fairSentiment is constructive but extended, with recent gains largely absorbed and no immediate catalysts.
The dominant driver is the announced 2026-10-28 Q3 beat-and-raise — adjusted EBITDA above $1B for the first time, FY2026 revenue guidance lifted to $10.975–11.175B — reinforced by a $50M buyback and full redemption of the ~$643M 8.5% 2027 notes, and the measured sentiment delta is a determinate improvement (baseline +0.17 → scoring +0.34/+0.41) with the Red-Flag Screen clean and no cap applied. What keeps this out of the top band is timing rather than tone: the reward is eight days old and largely absorbed, the stock is ~55% higher over October and trading above the only post-print sell-side target, and no forward-dated catalyst sits inside the 30-day window.
Technical
goodThe stock is in a strong uptrend, consolidating after a recent spike, with key levels supporting further gains.
Score 4: trend and momentum are strongly aligned — price 8.34 sits above every key moving average (SMA20 6.79, SMA50 6.33, SMA200 5.72, EMA9 7.68, EMA21 7.03) with MACD 0.58/0.37 (histogram +0.21) and ADX14 33.07 rising from 22.87 five sessions ago, and the planned R/R of 2.00 clears the ≥2.0 top-band criterion. The one weak signal is overbought RSI 71.60 combined with the 2026-10-30 −8.2% reversal off the 9.04 catalyst high and TEMA14 8.41 marginally above spot, which argues for bidding the 8.02–8.14 shelf rather than paying up into 8.46/9.04 resistance — hence 4, not 5.
You’re looking at 2026-11-05 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

